Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

BACKGROUND: Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this effect. We investigated the safety and efficacy of the combination of the IGF-1R antibody cixutum...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schwartz, Gary K, Tap, William D, Qin, Li-Xuan, Livingston, Michael B, Undevia, Samir D, Chmielowski, Bartosz, Agulnik, Mark, Schuetze, Scott M, Reed, Damon R, Okuno, Scott H, Ludwig, Joseph A, Keedy, Vicki, Rietschel, Petra, Kraft, Andrew S, Adkins, Douglas, Van Tine, Brian A, Brockstein, Bruce, Yim, Vincent, Bitas, Christiana, Abdullah, Abdul, Antonescu, Cristina R, Condy, Mercedes, Dickson, Mark A, Vasudeva, Shyamprasad Deraje, Ho, Alan L, Doyle, L Austin, Chen, Helen X, Maki, Robert G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3766955/
https://ncbi.nlm.nih.gov/pubmed/23477833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70049-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak